ASH 2022 Conference Coverage
MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
By
ASH 2022 Conference Coverage
FEATURING
Mary Frances McMullin
By
ASH 2022 Conference Coverage
FEATURING
Mary Frances McMullin
Login to view comments.
Click here to Login